Company profile · Sponsor
Philogen
Philogen S.p.A.
- Pipeline
- 18
- Drugs
- 0
- Patents
- 0
Quick answer
Philogen (E2619F9) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 18 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (18)
Search pipeline →-
Darleukin, Fibromun
Philogen
Malignant melanoma of the skin in patients with locally advanced and fully resectable melanoma with/without prior therapy and presence of injectable cutaneous and/or subcutaneous or nodal lesions
1 trial -
Doxorubicin 2 mg/ml Solution for Injection., Fibromun
Philogen
Unresectable or metastatic soft tissue sarcoma
1 trial -
Darleukin, Fibromun
Philogen
locally advanced basal cell carcinoma patients
1 trial -
Darleukin, Fibromun
Philogen
Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
1 trial -
Fibromun, Dacarbazine medac 1000 mg, powder for solution for infusion
Philogen
Unresectable and/or metastatic soft-tissue sarcoma after failure of at least two prior systemic therapy regimens.
1 trial -
Fibromun, Darleukin
Philogen
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention, including: • Basal cell carcinoma (BCC) • Cutaneous squamous cell carcinoma (cSCC) • Merkel cell carcinoma (MCC) • Keratoacanthoma (KA) • Malignant adnexal tumors of the skin (MATS) • Tumors from cutaneous T-cell lymphoma (CTCL) • Kaposi’s sarcoma (KS)
1 trial -
Fibromun, Darleukin
Philogen
Cutaneous Squamous Cell Carcinoma
1 trial -
Fibromun, Darleukin
Philogen
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable to intratumoral injection, who have progressed or intolerant to systemic treatment.
1 trial -
Fibromun, Temozolomide SUN 100 mg hard capsules
Philogen
Glioblastoma
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion., Darleukin, Fibromun
Philogen
Patients with diagnosis of unresectable clinical stage III or IV metastatic melanoma, with presence of injectable cutaneous, subcutaneous or nodal lesions and resistant to or progressing upon anti-PD1 immunotherapy
1 trial -
Lomustine "medac" 40 mg, Fibromun
Philogen
Glioblastoma
1 trial -
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer
Philogen
Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoCAIX in patients with CAIX-positive cancer
Philogen
Patients with suspected clear cell renal cell carcinoma (ccRCC)
1 trial -
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.
Philogen
Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands
1 trial -
A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.
Philogen
Advanced solid tumors, specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS), BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma
1 trial -
A dose-finding Phase I study of F8IL10 intra-articular treatment in Rheumatoid Arthritis
Philogen
Patients with Rheumatoid Arthritis (RA) who, despite treatment with stable doses (for at least 3 months) of disease-modifying antirheumatic drugs (DMARDs, conventional, biologic and/or targeted synthetic), present arthritis flare(s) suitable for intra-articular (IA) injection in a knee, shoulder, ankle, wrist or elbow.
1 trial -
A phase I study to evaluate the safety and preliminary signs of efficacy of [177Lu]Lu-OncoFAP-23 alone and in combination with L19-IL2 as a treatment of metastatic FAP-positive solid tumors.
Philogen
Patients with advanced/metastatic FAP-positive tumors
1 trial -
Safety and Early Signs of Efficacy of IL12-L19L19
Philogen
Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
1 trial
Frequently asked questions
What is Philogen?
Philogen (E2619F9) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 18 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Philogen sponsor?
We track 18 ClinicalTrials.gov-linked programs for Philogen, including Darleukin, Fibromun and 17 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Philogen company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.